MagPortal.com   Clustify - document clustering
 Home  |  News Feeds  |  Stock Market  |  Newsletter  |  My Articles  |  My Account  |  Affiliate Program  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
See Also
Health
Health / Illness, Injury & Treatments
Health / Medical Practice
Science & Technology / Biology & Life Sciences
Current Medical Articles
PHONE+
July 2, 2009
Case Study: SRSsoft Provides Customer Service at Optimum Speed SRSsoft integrates Optimum Lightpath's Ethernet-based communications solutions to maintain it's fast response time despite it's increasing number of clients. mark for My Articles
The Motley Fool
July 2, 2009
Robert Steyer
At Last, a Heartening Drug Approval French drug giant sanofi-aventis gets FDA approval for a drug to treat an erratic heartbeat. mark for My Articles similar articles
The Motley Fool
July 2, 2009
Brian Orelli
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. mark for My Articles similar articles
The Motley Fool
July 2, 2009
Brian Orelli
Deal Struck, Shares Stuck Acorda Therapeutics secured a decent upfront payment to license the ex-U.S. rights to its multiple sclerosis drug, Fampridine-SR, from the perfect partner. Unfortunately, investors still smacked the stock down nearly 15% yesterday. mark for My Articles similar articles
The Motley Fool
July 1, 2009
Brian Orelli
The Meat of a One-Drug Wonder AMAG announces that its iron replacement, Feraheme, was approved by the Food and Drug Administration. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
One-Drug Wonders Deserve a Spot in Your Portfolio Looking a little more appetizing these days. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
Following the Pack to Future Returns Mylan's playing catch up, but there's room for more. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. mark for My Articles similar articles
The Motley Fool
June 29, 2009
Brian Orelli
REMS: Not Just for Sleeping Anymore Risk Evaluation and Mitigation Strategies is saving drugmakers from going into a deep sleep while they wait for Food and Drug Administration approval of their drugs. mark for My Articles similar articles
The Motley Fool
June 29, 2009
Brian Orelli
Funding From an Unlikely Place Nonprofits still have money, and they seem willing to fork it over to for-profit drug companies. mark for My Articles similar articles
The Motley Fool
June 29, 2009
Brian Orelli
Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder. mark for My Articles similar articles
The Motley Fool
June 29, 2009
Brian Orelli
Lantus Results: Reply Hazy, Try Again Later Drugmaker Sanofi's problems become murkier. Investors are relieved that the data is out -- Sanofi is up about 4.5% at the moment -- but it seems prudent to be cautious here. mark for My Articles similar articles
The Motley Fool
June 29, 2009
Brian Orelli
Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug. mark for My Articles similar articles
The Motley Fool
June 29, 2009
Brian Orelli
Your Company Has Been Raided. What Now? Lately, investors have had to worry about pharmaceutical companies keeping their drugs on the market. mark for My Articles similar articles
The Motley Fool
June 26, 2009
Brian Orelli
Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer. mark for My Articles similar articles
The Motley Fool
June 26, 2009
Brian Orelli
Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market. mark for My Articles similar articles
The Motley Fool
June 26, 2009
Brian Orelli
Novartis Leads the Pack Biosimilars come to Japan; will the U.S. be next? In the U.S., the main hang-up is how much guaranteed patent protection branded biologics will be given. mark for My Articles similar articles
The Motley Fool
June 26, 2009
Brian Orelli
Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss. mark for My Articles similar articles
The Motley Fool
June 26, 2009
Brian Orelli
The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over. mark for My Articles similar articles
BusinessWeek
June 25, 2009
Catherine Arnst
The Family Doctor: A Remedy for Health-Care Costs? How making primary-care physicians the center of America's health-care system could drive down costs. mark for My Articles similar articles
The Motley Fool
June 25, 2009
Brian Orelli
Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well. mark for My Articles similar articles
The Motley Fool
June 25, 2009
Brian Orelli
Pfizer Gets a Double After a couple of disappointing trials for Pfizer's Sutent, investors get some good news about the drug. mark for My Articles similar articles
InternetNews
June 24, 2009
Kenneth Corbin
CTIA Seeking Mobile Health Care Mandate With an eye toward stimulus funds, wireless trade association convenes medical experts and policy makers to talk up remote-monitoring technologies. mark for My Articles similar articles
The Motley Fool
June 24, 2009
Brian Orelli
This Just Makes Me Sick! GlaxoSmithKline's anti-nausea medication Rezonic's marketing approval was turned down by the Food and Drug Administration, reason unknown. mark for My Articles similar articles
The Motley Fool
June 24, 2009
Brian Orelli
Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well. mark for My Articles similar articles
The Motley Fool
June 23, 2009
Brian Orelli
A Pharma Proposal Homer Simpson Could Love Drug companies have pledged to hand out $80 billion worth of doughnut holes over the next decade to low- and middle-income seniors, complete with a side of good PR. mark for My Articles similar articles
The Motley Fool
June 23, 2009
Brian Orelli
Wonder Drug! Maybe? Get the facts before jumping on this one. mark for My Articles similar articles
The Motley Fool
June 22, 2009
Jim Mueller
Dendreon: Cash Out or Keep Riding Up? Given Dendreon's rise this year and Provenge's prospects, what should a prudent investor do? mark for My Articles similar articles
Fast Company
July 2009
Kate Rockwood
How BodyMedia Is Making Fitness Data Personal Ivo Stivoric has developed wearable fitness sensors for clinical patients for more than a decade. Responding to demand, BodyMedia introduced its GoWear fit line for consumers last year. mark for My Articles
Fast Company
July 2009
Kate Rockwood
Gadi Amit on Designing a Lifestyle App for the Networked Body The Fitbit Tracker is an activity monitor that calculates your steps, calories burned, and sleep patterns. mark for My Articles similar articles
Fast Company
July 2009
Kate Rockwood
How Mayo Clinic and Microsoft Are Empowering Patients The Mayo Clinic Health Manager free Web application, launched in April, supports data from health-monitoring devices, stores family medical records using Microsoft's HealthVault, and offers guidance and reminders from the Mayo Clinic. mark for My Articles similar articles
Fast Company
July 2009
Kate Rockwood
How Body Sensors Are Gaming the Health System A social online game called Wellness Partners awards virtual "energy points" for real-world physical activity. mark for My Articles similar articles
Fast Company
July 2009
Kate Rockwood
How the Networked Body Is Reinventing the Consumer A short conversation with Leslie Saxon, who has worked in the field of networked health monitoring for 17 years. mark for My Articles similar articles
Fast Company
July 2009
Kate Rockwood
How Toumaz Is Building a Complete Ecosystem for the Networked Body Alison Burdett developed the Sensium, a tiny chip-based wireless system for medical-device developers; it consumes up to 100 times less energy than other chips for wireless body-monitoring networks. mark for My Articles similar articles
Fast Company
July 2009
Zachary Wilson
Why Walgreens Is Building Its Own Universal Health-Care System Walgreens, the $59 billion drugstore giant, is building its own universal health-care system, with more than 700 retail and corporate clinics. mark for My Articles similar articles
The Motley Fool
June 19, 2009
Brian Orelli
Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk. mark for My Articles similar articles
The Motley Fool
June 19, 2009
Robert Steyer
MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical. mark for My Articles similar articles
The Motley Fool
June 19, 2009
Brian Orelli
Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies. mark for My Articles similar articles
The Motley Fool
June 18, 2009
Brian Orelli
Your Stocks Just Got Riskier It's been a busy week for the Food and Drug Administration, and not in the bust-out-the-champagne-we-got-an-approval way. Is the FDA cracking down on pharmaceutical companies? mark for My Articles similar articles
The Motley Fool
June 18, 2009
Daniel Harrison
Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains. mark for My Articles similar articles
BusinessWeek
June 17, 2009
Catherine Arnst
Why the AMA Will Likely Support Health-Care Reform Obama's plan might lower specialists' pay, but it would help primary-care doctors, save the industry billions, and please voters. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2009
Pay For Play The P4P movement is here. Pharma marketers, it's time to take note. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2009
Stealth Pharmas These noteworthy pharmas and biotechs generally fly under the radar (ergo "stealth") of the mainstream media. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2009
Emerging Leaders 2009: The Faces of Innovation Meet 2009's emerging leaders - 27 industry pioneers under age 45 who are bringing new ideas to life. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2009
John F. Kouten
On the Right Pathways With staggering year-over-year growth, biosimilars are "the future of medicine." Marketers must position their companies for the inevitable changes. President Barack Obama has pledged support for legislation governing biosimilars. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2009
Michael Maher
Learning to Relate A multi-phase implementation strategy can debunk the myth that social media won't work for pharma. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2009
Patrick Clinton
High School Justice FDA slaps down Cheerios and forces pharma companies that use Google to make technical changes no consumer will ever notice. Big whoop. mark for My Articles similar articles
The Motley Fool
June 17, 2009
Brian Orelli
Savient Saves and Moves Up The FDA advisory panel gives Savient's Krystexxa a passing grade. mark for My Articles similar articles
The Motley Fool
June 16, 2009
Brian Orelli
Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs. mark for My Articles similar articles
Chemistry World
June 15, 2009
Matt Wilkinson
Concert arranges billion dollar GSK deal US-based Concert Pharmaceuticals has inked its first commercialization deal granting GlaxoSmithKline access to six deuterium-modified drugs mark for My Articles similar articles
Inc.
June 2009
Nicole Marie Richardson
Innovation: CardioMEMS EndoSure Sensor CardioMEMS creates body sensors that monitor cardiovascular health. mark for My Articles similar articles
Chemistry World
June 5, 2009
Anna Lewcock
Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts. mark for My Articles similar articles
Chemistry World
June 2009
Derek Lowe
Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration mark for My Articles similar articles
Chemistry World
May 21, 2009
Matt Wilkinson
Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets. mark for My Articles similar articles
Chemistry World
May 21, 2009
Rebecca Trager
FDA gets new chief The US Food and Drug Administration's (FDA) new commissioner, Margaret Hamburg, will be the second woman to ever lead FDA mark for My Articles similar articles
There are 5914 old articles available for this category.